{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:06:57Z","timestamp":1790737617000,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"am","delay-in-days":415,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013829","name":"Alfred E. Mann Institute for Biomedical Engineering, University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jconrel.2020.10.047","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T22:13:37Z","timestamp":1603836817000},"page":"1198-1209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease"],"prefix":"10.1016","volume":"329","author":[{"given":"Jonathan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Hallows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jconrel.2020.10.047_bb0005","first-page":"742","article-title":"Progress in Nanomedicine: approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P & T: Peer-rev. J. Formul. Manag."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"issue":"5665","key":"10.1016\/j.jconrel.2020.10.047_bb0015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.10.047_bb0020","doi-asserted-by":"crossref","first-page":"1900196","DOI":"10.1002\/adtp.201900196","article-title":"Collagenase-cleavable peptide amphiphile micelles as a novel theranostic strategy in atherosclerosis","author":"Chin","year":"2020","journal-title":"Adv. Therapeutics"},{"issue":"41","key":"10.1016\/j.jconrel.2020.10.047_bb0025","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1039\/C9TB01918A","article-title":"Hydroxyapatite-binding micelles for the detection of vascular calcification in atherosclerosis","volume":"7","author":"Chin","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/2472630317738699","article-title":"Theranostic nanoparticles for tracking and monitoring disease state","volume":"23","author":"Zavaleta","year":"2017","journal-title":"SLAS Technol.: Transl. Life Sci. Innov."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.biomaterials.2018.07.030","article-title":"Folate-conjugated nanobubbles selectively target and kill cancer cells via ultrasound-triggered intracellular explosion","volume":"181","author":"Shen","year":"2018","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.jconrel.2020.10.047_bb0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1756283X17705328","article-title":"Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer","volume":"10","author":"Rahman","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12883-019-1354-y","article-title":"An update on peginterferon beta-1a management in multiple sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and Dermatologists","volume":"19","author":"Kolb-M\u00e4urer","year":"2019","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0050","doi-asserted-by":"crossref","first-page":"FSO230","DOI":"10.4155\/fsoa-2017-0069","article-title":"Advances in nanomedicine drug delivery applications for HIV therapy","volume":"4","author":"Curley","year":"2017","journal-title":"Future Sci. OA"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0055","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","article-title":"Estimating prevalence in single-gene kidney diseases progressing to renal failure","volume":"58","author":"Levy","year":"2000","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.jconrel.2020.10.047_bb0060","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1039\/C7BM00271H","article-title":"Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease","volume":"5","author":"Wang","year":"2017","journal-title":"Biomater. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2020.10.047_bb0065","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1007\/s12274-018-2100-2","article-title":"Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery","volume":"11","author":"Wang","year":"2018","journal-title":"Nano Res."},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0070","first-page":"393","article-title":"Developments in the management of autosomal dominant polycystic kidney disease","volume":"4","author":"Masoumi","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int."},{"issue":"Suppl_1","key":"10.1016\/j.jconrel.2020.10.047_bb0080","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/ckj\/sfy103","article-title":"Management of autosomal-dominant polycystic kidney disease\u2014State-of-the-art","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin. Kidney J."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/13543781003588491","article-title":"Novel targets for the treatment of autosomal dominant polycystic kidney disease","volume":"19","author":"Belibi","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1573402111309010008","article-title":"Experimental therapies and ongoing clinical trials to slow down progression of ADPKD","volume":"9","author":"Irazabal","year":"2013","journal-title":"Curr. Hypertens. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0095","doi-asserted-by":"crossref","first-page":"F535","DOI":"10.1152\/ajprenal.00242.2018","article-title":"\u201cFirst do no harm\u201d: kidney drug targeting to avoid toxicity in ADPKD","volume":"315","author":"Chung","year":"2018","journal-title":"Am. J. Physiol.-Renal Physiol."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0100","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0105","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jdi.12755","article-title":"Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus","volume":"9","author":"Kanto","year":"2017","journal-title":"J. Diab. Invest."},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-017-0804-2","article-title":"A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD outcomes model","volume":"19","author":"McEwan","year":"2018","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1995-705X.132136","article-title":"Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India","volume":"15","author":"Patra","year":"2014","journal-title":"Heart Views: Off. J. Gulf Heart Assoc."},{"issue":"20","key":"10.1016\/j.jconrel.2020.10.047_bb0130","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2020.10.047_bb0135","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.nano.2014.08.006","article-title":"In vivo biodistribution and clearance of peptide amphiphile micelles","volume":"11","author":"Chung","year":"2015","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40744-017-0080-4","article-title":"Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment","volume":"4","author":"Schiff","year":"2017","journal-title":"Rheumatol. Therapy"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent Progress in Oral drug delivery Systems for Biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2020.10.047_bb0155","series-title":"in Drug Delivery Systems","first-page":"217","article-title":"Extended-release oral drug delivery technologies: monolithic matrix systems","author":"Tiwari","year":"2008"},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/17425247.2019.1610384","article-title":"Oral delivery of nanoparticles - let\u2019s not forget about the protein corona","volume":"16","author":"Berardi","year":"2019","journal-title":"Expert Opinion Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0165","first-page":"765","article-title":"Recent advances of chitosan nanoparticles as drug carriers","volume":"6","author":"Wang","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.10.047_bb0170","doi-asserted-by":"crossref","first-page":"e2833","DOI":"10.1590\/1518-8345.1457.2833","article-title":"Risk factors for complications in peripheral intravenous catheters in adults: secondary analysis of a randomized controlled trial","volume":"24","author":"Johann","year":"2016","journal-title":"Revista latino-americana de enfermagem"},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J. Adv. Nurs."},{"issue":"10 Suppl","key":"10.1016\/j.jconrel.2020.10.047_bb0180","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/AJP.0000000000000273","article-title":"Interventions for individuals with high levels of needle fear: systematic review of randomized controlled trials and quasi-randomized controlled trials","volume":"31","author":"McMurtry","year":"2015","journal-title":"Clin. J. Pain"},{"issue":"32","key":"10.1016\/j.jconrel.2020.10.047_bb0185","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/16506073.2016.1157204","article-title":"Exposure-based interventions for the management of individuals with high levels of needle fear across the lifespan: a clinical practice guideline and call for further research","volume":"45","author":"McMurtry","year":"2016","journal-title":"Cogn. Behav. Ther."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0195","first-page":"172","article-title":"Fear of needles nature and prevalence in general practice","volume":"38","author":"Wright","year":"2009","journal-title":"Aust. Fam. Physician"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0205","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1080\/10717544.2018.1501119","article-title":"The challenges of oral drug delivery via nanocarriers","volume":"25","author":"Reinholz","year":"2018","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2009.05.038","article-title":"Intestinal barrier function: molecular regulation and disease pathogenesis","volume":"124","author":"Groschwitz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0215","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198409010-00001","article-title":"First-pass elimination basic concepts and clinical consequences","volume":"9","author":"Pond","year":"1984","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0225","first-page":"2016","article-title":"Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs","author":"Mayank Sharma","year":"2016","journal-title":"Scientifica"},{"issue":"4","key":"10.1016\/j.jconrel.2020.10.047_bb0230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics9040053","article-title":"An overview of chitosan nanoparticles and its application in non-parenteral drug delivery","volume":"9","author":"Mohammed","year":"2017","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1081\/PDT-100100522","article-title":"Mucoadhesive DL-lactide\/glycolide copolymer Nanospheres coated with chitosan to improve Oral delivery of Elcatonin","volume":"5","author":"Kawashima","year":"2000","journal-title":"Pharm. Dev. Technol."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0240","first-page":"411","article-title":"Chitin and chitosan: production and application of versatile biomedical Nanomaterials","volume":"4","author":"Elieh-Ali-Komi","year":"2016","journal-title":"Int. J. Adv. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2020.10.047_bb0245","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.mib.2010.05.002","article-title":"Chitin synthesis and fungal pathogenesis","volume":"13","author":"Lenardon","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"issue":"26","key":"10.1016\/j.jconrel.2020.10.047_bb0250","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1016\/j.polymer.2003.10.025","article-title":"Contribution to the preparation of chitins and chitosans with controlled physico-chemical properties","volume":"44","author":"Tolaimate","year":"2003","journal-title":"Polymer"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0255","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/md13031133","article-title":"Chitin and chitosan preparation from marine sources. Structure, properties and applications","volume":"13","author":"Younes","year":"2015","journal-title":"Marine Drugs"},{"issue":"8","key":"10.1016\/j.jconrel.2020.10.047_bb0260","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.3390\/md13085156","article-title":"Chitosan: an update on potential biomedical and pharmaceutical applications","volume":"13","author":"Cheung","year":"2015","journal-title":"Marine Drugs"},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/md14050099","article-title":"\"The good, the bad and the ugly\" of chitosans","volume":"14","author":"Bellich","year":"2016","journal-title":"Marine Drugs"},{"key":"10.1016\/j.jconrel.2020.10.047_bb0270","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.carbpol.2014.03.056","article-title":"Production of microparticles with gelatin and chitosan","volume":"116","author":"Prata","year":"2015","journal-title":"Carbohydr. Polym."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0275","first-page":"178","article-title":"Fabrication and evaluation of porous keratin\/chitosan (KCS) scaffolds for effectively accelerating wound healing","volume":"28","author":"Tan","year":"2015","journal-title":"Biomed. Environ. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0280","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomed. (London, England)"},{"issue":"12","key":"10.1016\/j.jconrel.2020.10.047_bb0285","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1021\/la500491c","article-title":"Characterization of self-assembled polyelectrolyte complex nanoparticles formed from chitosan and pectin","volume":"30","author":"Birch","year":"2014","journal-title":"Langmuir"},{"issue":"8","key":"10.1016\/j.jconrel.2020.10.047_bb0290","first-page":"613","article-title":"Thiomer nanoparticles: stabilization via covalent cross-linking","volume":"18","author":"Barthelmes","year":"2011","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/nano.2006.1.2.117","article-title":"Chitosan nanoparticles for oral drug and gene delivery","volume":"1","author":"Bowman","year":"2006","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0300","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/21691401.2014.948548","article-title":"Advances in preparation and characterization of chitosan nanoparticles for therapeutics","volume":"44","author":"Chandra Hembram","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"11","key":"10.1016\/j.jconrel.2020.10.047_bb0305","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1248\/cpb.58.1423","article-title":"Chitosan nanoparticles: a promising system in novel drug delivery","volume":"58","author":"Nagpal","year":"2010","journal-title":"Chem. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4","article-title":"Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers","volume":"63","author":"Calvo","year":"1997","journal-title":"J. Appl. Polym. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2020.10.047_bb0315","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1021\/mp300162j","article-title":"Insight on the formation of chitosan nanoparticles through Ionotropic gelation with Tripolyphosphate","volume":"9","author":"Koukaras","year":"2012","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0320","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1038\/s41598-018-23064-4","article-title":"Parameters influencing the size of chitosan-TPP nano- and microparticles","volume":"8","author":"Sreekumar","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0325","doi-asserted-by":"crossref","first-page":"22260","DOI":"10.1038\/srep22260","article-title":"Chitosan nanoparticles synthesis caught in action using microdroplet reactions","volume":"6","author":"Kamat","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejps.2017.11.020","article-title":"Novel controlled ionic gelation strategy for chitosan nanoparticles preparation using TPP-\u03b2-CD inclusion complex","volume":"112","author":"Pant","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biomaterials.2017.03.028","article-title":"Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin","volume":"130","author":"He","year":"2017","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.jconrel.2020.10.047_bb0340","doi-asserted-by":"crossref","first-page":"1901935","DOI":"10.1002\/adma.201901935","article-title":"Oral delivery of biologics for precision medicine","volume":"32","author":"Dur\u00e1n-Lobato","year":"2020","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0345","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-5173(02)00461-1","article-title":"Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A","volume":"249","author":"El-Shabouri","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2013.08.037","article-title":"Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment","volume":"456","author":"Bagre","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","article-title":"Clinical pharmacokinetics of metformin","volume":"30","author":"Scheen","year":"1996","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0360","first-page":"483","article-title":"Simple HPLC-UV method for the quantification of metformin in human plasma with one step protein precipitation","volume":"22","author":"Chhetri","year":"2014","journal-title":"Saudi Pharmaceutical J.: SPJ: Off. Publ. Saudi Pharmaceutical Soc."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0365","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0250-474X.56022","article-title":"Spectrophotometric quantitation of metformin in bulk drug and pharmaceutical formulations using multivariate technique","volume":"71","author":"Arayne","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"issue":"14","key":"10.1016\/j.jconrel.2020.10.047_bb0370","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/macp.200800191","article-title":"Straightforward determination of the degree of N-acetylation of chitosan by means of first-derivative UV spectrophotometry","volume":"209","author":"da Silva","year":"2008","journal-title":"Macromol. Chem. Phys."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0375","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","article-title":"The use of biorelevant dissolution media to forecast the in vivo performance of a drug","volume":"12","author":"Klein","year":"2010","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.jconrel.2020.10.047_bb0380","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.tiv.2012.03.009","article-title":"Good Caco-2 cell culture practices","volume":"26","author":"Natoli","year":"2012","journal-title":"Toxicol. in Vitro"},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0385","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.V105923","article-title":"Corticosteroid-dependent sodium transport in a novel immortalized mouse collecting duct principal cell line","volume":"10","author":"Bens","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejps.2003.10.002","article-title":"Effect of insulin on cephalexin uptake and transepithelial transport in the human intestinal cell line Caco-2","volume":"21","author":"Watanabe","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0395","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/mp400685v","article-title":"Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific Trimethyl chitosan nanoparticles","volume":"11","author":"Zhang","year":"2014","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2020.10.047_bb0400","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ng.2715","article-title":"Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease","volume":"45","author":"Ma","year":"2013","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.jconrel.2020.10.047_bb0405","doi-asserted-by":"crossref","first-page":"e0163063","DOI":"10.1371\/journal.pone.0163063","article-title":"An empirical biomarker-based calculator for cystic index in a model of autosomal recessive polycystic kidney disease-the Nieto-Narayan formula","volume":"11","author":"Nieto","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0410","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nano.2009.06.002","article-title":"Preparation of chitosan nanoparticles containing Naja naja oxiana snake venom","volume":"6","author":"Mohammadpourdounighi","year":"2010","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0415","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/10717540490280705","article-title":"Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics","volume":"11","author":"Bozkir","year":"2004","journal-title":"Drug Deliv."},{"issue":"20","key":"10.1016\/j.jconrel.2020.10.047_bb0420","doi-asserted-by":"crossref","first-page":"11370","DOI":"10.1021\/la801917a","article-title":"A novel synthesis of chitosan nanoparticles in reverse emulsion","volume":"24","author":"Brunel","year":"2008","journal-title":"Langmuir"},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0425","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2016014850","article-title":"Chitosan nanoparticles prepared by ionotropic gelation: an overview of recent advances","volume":"33","author":"Desai","year":"2016","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0430","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/polym10030235","article-title":"Chitosan based self-assembled nanoparticles in drug delivery","volume":"10","author":"Qui\u00f1ones","year":"2018","journal-title":"Polymers"},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0435","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12342","article-title":"Mucus as a barrier to drug delivery \u2013 Understanding and mimicking the barrier properties","volume":"116","author":"Boegh","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0440","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0445","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/polym10030267","article-title":"Chitosan and its derivatives for application in mucoadhesive drug delivery systems","volume":"10","author":"Ways","year":"2018","journal-title":"Polymers"},{"issue":"4, Part 2","key":"10.1016\/j.jconrel.2020.10.047_bb0450","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0091-6749(86)90047-3","article-title":"Physiologic considerations in drug absorption from the gastrointestinal tract","volume":"78","author":"Golub","year":"1986","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0455","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.addr.2013.01.003","article-title":"In vitro and in vivo models for the study of oral delivery of nanoparticles","volume":"65","author":"Gamboa","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0460","first-page":"32","article-title":"Interaction between chitosan and mucin: fundamentals and applications","volume":"4","author":"Collado-Gonz\u00e1lez","year":"2019","journal-title":"Biomimetics (Basel, Switzerland)"},{"issue":"12","key":"10.1016\/j.jconrel.2020.10.047_bb0465","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/md15120370","article-title":"Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration","volume":"15","author":"Silva","year":"2017","journal-title":"Marine Drugs"},{"issue":"7\u20138","key":"10.1016\/j.jconrel.2020.10.047_bb0470","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/1061186X.2015.1086359","article-title":"Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids","volume":"23","author":"Yildiz","year":"2015","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0475","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11051-020-04785-y","article-title":"Effect of particle size and surface charge of nanoparticles in penetration through intestinal mucus barrier","volume":"22","author":"Bandi","year":"2020","journal-title":"J. Nanopart. Res."},{"issue":"17","key":"10.1016\/j.jconrel.2020.10.047_bb0480","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1021\/acs.langmuir.7b00351","article-title":"PEGylated Nanoemulsions for Oral delivery: role of the inner Core on the final fate of the formulation","volume":"33","author":"Santander-Ortega","year":"2017","journal-title":"Langmuir"},{"issue":"4","key":"10.1016\/j.jconrel.2020.10.047_bb0485","first-page":"413","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharmaceutical J.: SPJ: Off. Publ. Saudi Pharmaceutical Soc."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0490","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1007\/s10570-019-02357-5","article-title":"pH-responsive cellulose\u2013chitosan nanocomposite films with slow release of chitosan","volume":"26","author":"Yang","year":"2019","journal-title":"Cellulose"},{"key":"10.1016\/j.jconrel.2020.10.047_bb0495","first-page":"2012","article-title":"Chitosan nanoparticles as a percutaneous drug delivery system for hydrocortisone","author":"Haliza Katas","year":"2012","journal-title":"J. Nanomater."},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01684","article-title":"Degradability of chitosan micro\/nanoparticles for pulmonary drug delivery","volume":"5","author":"Islam","year":"2019","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.jconrel.2020.10.047_bb0505","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0379-0738(87)90045-4","article-title":"Experimental studies on the presumption of the time after food intake from stomach contents","volume":"35","author":"Suzuki","year":"1987","journal-title":"Forensic Sci. Int."},{"issue":"4","key":"10.1016\/j.jconrel.2020.10.047_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9040053","article-title":"An overview of chitosan nanoparticles and its application in non-parenteral drug delivery","volume":"9","author":"Mohammed","year":"2017","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jconrel.2020.10.047_bb0515","article-title":"Stable chitosan-based nanoparticles using polyphosphoric acid or hexametaphosphate for tandem ionotropic\/covalent crosslinking and subsequent investigation as novel vehicles for drug delivery","volume":"8","author":"Saeed","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"6S","key":"10.1016\/j.jconrel.2020.10.047_bb0520","first-page":"01","article-title":"A review on chitosan nanoparticles applications in drug delivery","volume":"7","author":"Sheetal","year":"2018","journal-title":"J. Pharmacog. Phytochem."},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0525","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/mp200572t","article-title":"Opening of epithelial tight junctions and enhancement of Paracellular permeation by chitosan: microscopic, Ultrastructural, and computed-tomographic observations","volume":"9","author":"Sonaje","year":"2012","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0530","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41551-019-0465-5","article-title":"Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability","volume":"4","author":"Lamson","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2020.10.047_bb0535","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0955-2863(01)00208-X","article-title":"The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line","volume":"13","author":"Ranaldi","year":"2002","journal-title":"J. Nutr. Biochem."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0540","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.addr.2012.10.007","article-title":"Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery","volume":"65","author":"Yun","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0545","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijbiomac.2019.07.168","article-title":"Cellular uptake and transport characteristics of chitosan modified nanoparticles in Caco-2 cell monolayers","volume":"138","author":"Dou","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0550","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2020.01.006","article-title":"Novel and revisited approaches in nanoparticle systems for buccal drug delivery","volume":"320","author":"Macedo","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.10.047_bb0555","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fphar.2017.00781","article-title":"Experimental evaluation of the transport mechanisms of PoIFN-\u03b1 in Caco-2 cells","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2020.10.047_bb0560","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0565","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?","volume":"19","author":"Pisani","year":"2018","journal-title":"BMC Nephrol."},{"issue":"6","key":"10.1016\/j.jconrel.2020.10.047_bb0570","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M114.604421","article-title":"Metformin activates AMP-activated protein kinase by promoting formation of the \u03b1\u03b2\u03b3 heterotrimeric complex","volume":"290","author":"Meng","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"7436","key":"10.1016\/j.jconrel.2020.10.047_bb0575","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jconrel.2020.10.047_bb0580","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI9622","article-title":"Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase","volume":"105","author":"Hallows","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2020.10.047_bb0585","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ki.1996.304","article-title":"The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro","volume":"50","author":"Davidow","year":"1996","journal-title":"Kidney Int."},{"issue":"34","key":"10.1016\/j.jconrel.2020.10.047_bb0590","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1073\/pnas.1305882110","article-title":"Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres","volume":"110","author":"Reineke","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.10.047_bb0595","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2016.06.016","article-title":"Nanoparticles for oral delivery: design, evaluation and state-of-the-art","volume":"240","author":"Date","year":"2016","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"42","key":"10.1016\/j.jconrel.2020.10.047_bb0600","doi-asserted-by":"crossref","first-page":"43940","DOI":"10.1074\/jbc.M404421200","article-title":"Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo: role of mitochondrial reactive nitrogen species","volume":"279","author":"Zou","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2020.10.047_bb0605","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease","volume":"17","author":"Smith","year":"2006","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:03:41Z","timestamp":1759161821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920306258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":121,"alternative-id":["S0168365920306258"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.047","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}